Stockscreener 앱 받기
23.04
6.04%
-1.48
전일 마감가:
$24.52
열려 있는:
$24.17
하루 거래량:
1.72M
Relative Volume:
1.54
시가총액:
$1.95B
수익:
$42.95M
순이익/손실:
$-130.01M
주가수익비율:
-14.15
EPS:
-1.6278
순현금흐름:
$-19.66M
1주 성능:
-4.83%
1개월 성능:
+39.47%
6개월 성능:
-5.11%
1년 성능:
+338.02%
1일 변동 폭
$22.30
$24.17
1주일 범위
$22.30
$24.98
52주 변동 폭
$4.12
$25.77
Monte Rosa Therapeutics Inc Stock (GLUE) Company Profile
명칭
Monte Rosa Therapeutics Inc
전화
617-949-2643
주소
321 HARRISON AVENUE, BOSTON
Compare GLUE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GLUE
Monte Rosa Therapeutics Inc
|
23.04 | 1.95B | 42.95M | -130.01M | -19.66M | -1.6278 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monte Rosa Therapeutics Inc Stock (GLUE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-01-03 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-13 | 개시 | UBS | Buy |
| 2022-08-15 | 개시 | Jefferies | Buy |
| 2022-04-28 | 개시 | Credit Suisse | Neutral |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
모두보기
Monte Rosa Therapeutics Inc 주식(GLUE)의 최신 뉴스
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Down 8.7%Here's What Happened - MarketBeat
Monte Rosa Therapeutics (GLUE) Recast As A Growth Name As Valuation Questions Build - simplywall.st
T. Rowe Price reports 8.86M-share stake in Monte Rosa Therapeutics (GLUE) - Stock Titan
Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 - Investing.com
Form 4 Monte Rosa Therapeutics Inc For: 7 July By Investing.com - Investing.com Canada
Monte Rosa Therapeutics CSO Sharon Townson sells shares worth $139,849 By Investing.com - Investing.com Canada
Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares after option exercise - Stock Titan
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Up 6.9%Should You Buy? - MarketBeat
AUPH Stock Price and Chart — NASDAQ:AUPH - TradingView
Form 4 Monte Rosa Therapeutics Inc For: 6 July By Investing.com - Investing.com Nigeria
Form 13D/A Monte Rosa Therapeutics For: 6 July By Investing.com - Investing.com Canada
NEA funds shift 1,000,000 Monte Rosa shares (NASDAQ: GLUE) - Stock Titan
NEA adjusts Monte Rosa Therapeutics (GLUE) stake with share distribution and sales - Stock Titan
GLUEMonte Rosa Therapeutics Inc Volatility & Greeks - Finviz
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Monte Rosa lures 3 new hires with stock awards worth 18,025 options - Stock Titan
Form 4 Monte Rosa Therapeutics Inc For: 1 July By Investing.com - Investing.com Nigeria
Monte Rosa CMO Filip Janku sells $132k in company stock - Investing.com
Filip Janku Sells 5,407 Shares of Monte Rosa Therapeutics (NASDAQ:GLUE) Stock - MarketBeat
Monte Rosa Therapeutics (NASDAQ: GLUE) CMO trades 5,407 shares under 10b5-1 plan - Stock Titan
Form 144 Monte Rosa Therapeutics For: 30 June By Investing.com - Investing.com Australia
Form 4 Monte Rosa Therapeutics Inc For: 30 June By Investing.com - Investing.com South Africa
Monte Rosa director Anthony Manning sells $231,100 in GLUE shares By Investing.com - Investing.com Nigeria
Monte Rosa director Anthony Manning sells $231,100 in GLUE shares - Investing.com
GLUE (NASDAQ: GLUE) affiliate reports option exercise and 10b5-1 sales in June 2026 - Stock Titan
Monte Rosa Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Monte Rosa (NASDAQ: GLUE) CMO exercises options, sells 6,000 shares - Stock Titan
Monte Rosa (NASDAQ: GLUE) director exercises options, sells 10,000 shares at $23.11 - Stock Titan
Guggenheim raises Monte Rosa stock price target on pipeline potential - Investing.com UK
Guggenheim raises Monte Rosa stock price target on pipeline potential By Investing.com - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
After a 400% Surge, Should Investors Care About This $882,000 Monte Rosa Insider Sale? - The Motley Fool
GLUE (NASDAQ: GLUE) option exercise; insider 10b5-1 sales total 41,845 shares - Stock Titan
Anthony Manning sells 10,000 GLUE shares; option exercise planned (GLUE) - Stock Titan
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2000 Value Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2000 Growth Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 3000E Growth Benchmark - marketscreener.com
Does Monte Rosa Therapeutics' (GLUE) Shift Into Russell Growth Indices Recast Its Biotech Risk Profile? - simplywall.st
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 3000E Value Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Monte Rosa Therapeutics, Inc. Actuals & Estimates (NASDAQ:GLUE) - TradingView
Monte Rosa (GLUE) CMO sells 41,845 shares after exercising options - Stock Titan
Monte Rosa (NASDAQ: GLUE) COO exercises stock options, sells 2,175 shares - Stock Titan
GLUE Forecast — Price Target — Prediction for 2027 - TradingView
Insider exercises 30,000 shares; sells 11,845 under 10b5-1 (GLUE) - Stock Titan
Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $29 - Moomoo
Monte Rosa Therapeutics Inc (GLUE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):